


Abstracts from the HTAi 2019 Annual Meeting
in Cologne, Germany, June 15-19

International Journal of

Technology Assessment in Health Care

HTA Beyond 2020: Ready for a New Decade?



International Journal of Technology Assessment in Health Care

Official Journal of Health Technology Assessment International

Editor-in-Chief

Wendy Babidge, PhD, BApp Sci (Hons), Grad Dip Bus, FIML, GAICD, PGCert HEHCP York

General Manager Research, Audit and Academic Surgery, Royal Australasian College of Surgeons

Adjunct Associate Professor, University of Adelaide

199 Ward St, North Adelaide South Australia 5006, Australia

Email: wendy.babidge@adam.com.au

Aims and Scope: The *International Journal of Technology Assessment in Health Care* has as its specific scope of interest the generation, evaluation, diffusion, and use of health care technology. It addresses the diverse audience of health care providers within medicine, public health, nursing, and the allied health professions; decision makers in government, industry, and health care organizations; and the scholarly disciplines such as ethics, economics, law, history, sociology, psychology, and engineering. The journal aims to fill the needs of those interested in the complexities of interaction between people and technology; technology as a force in social and organizational change; and technology as it is created, produced, applied, and paid for. It examines descriptively and analytically the effects of technology as perceived from the vantage point of different academic disciplines and policy-making organizations and examines methods necessary to conduct studies and evaluations of technology.

The focus of the journal is the international health care community. The experience of different countries in their encounter with health care technology, viewed comparatively, is invaluable to understanding its effects. Further, it is important to establish ties with the scholars, governments, and private institutions concerned with health care technology so that the experiences and learning of the international community in its parts can benefit the whole. The use of technology in health care has created some of the major dilemmas in society today. The journal serves as a forum for the wide range of professionals interested in the assessment of medical technology, its consequences for patients, and its impact on society.

Publishing, Advertising, and Subscription Offices: Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. (for U.S.A., Canada, and Mexico); or Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK (for U.K. and elsewhere).

2018 Subscription Information: *International Journal of Technology Assessment in Health Care* (ISSN 0266-4623) is

published bimonthly in February, April, June, August, October, and December by Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006; Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK. Annual institutional subscription rates for Volume 34 (2018): Institutions online only US \$593.00, and online only UK and elsewhere £341.00. Individuals online only US \$343.00, and online only UK and elsewhere £193.00. Single part: US \$114.00 in the U.S.A., Canada and Mexico; UK £65.00 and elsewhere. Online only for all institutions. Print editions ceased in 2014. Back volume prices are available upon request. *International Journal of Technology Assessment in Health Care* and other Cambridge journals can be found at <http://journals.cambridge.org>

© Cambridge University Press 2019

All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions.permission.htm>

Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center, <http://www.copyright.com>, email: info@copyright.com.

Postmaster: Send address changes in the U.S.A. and Canada to: *International Journal of Technology Assessment in Health Care*, Journals Department, Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. Send address changes elsewhere to: *International Journal of Technology Assessment in Health Care*, Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK.

Founding Editors: Egon Jonsson and Stanley J. Reiser

Contents

Oral Presentations	1
OP06 Evaluating Public Health Interventions: A Neglected Area In HTA.....	1
OP10 Approaches To Gain Reimbursement For Medical Devices In Germany.....	1
OP14 Progress In Use Of Telerehabilitation For Persons With COPD.....	2
OP15 Use Of Digital Health Information Among HIV Populations In Uganda.....	2
OP16 Assessing The Viability Of Medical Equipment Procurement In Hospital.....	2
OP18 A Case Study Of Local Context-Dependent Decision-Making In Health Technology Assessment.....	3
OP19 Does The HST Represent A Best Practice Model For Ultra-Orphan HTA?.....	3
OP20 Has The New HST Process Improved The Recommendation Chance In England?.....	4
OP21 Enhancing Capability: Patient Impact In Ultra-Orphan Conditions.....	4
OP22 Patient-Based Evidence: Its Role In Decision-Making On New Medicines.....	4
OP23 Smart Searches For Context-Sensitive Topics: Geographic Search Filters.....	5
OP25 Organisational Learning Principles Applied To Information Retrieval.....	5
OP26 Search Approaches In Information Retrieval Presented In HTAi SuRe Info.....	5
OP27 Engaging Patients: The EuroCAB Programme.....	6
OP28 Patient Involvement at AQUAS: Experiences And Reflections For Future.....	6
OP29 Building A Global, Public Repository Of Patient Experience Data.....	7
OP30 Impact Of Patient Reported Outcomes Data On Health Technology Assessments Of Acute Myeloid Leukemia.....	7
OP31 HTA And Patients' Preferences: Starting A Discrete Choice Experiment.....	7
OP33 Treatment Of Mitral Insufficiency And Multicriteria Decision-Making.....	8
OP34 One-Way Sensitivity Analysis For Cost Effectiveness Analysis.....	8
OP37 Impact On Uncertainty Of Disaggregating Cost Data.....	8
OP38 Implementing Social Innovations: From Evidence-Based To Theory-Driven.....	9
OP39 Adapting HTA To Suit Emerging Needs - An Australian Experience.....	9
OP40 Criminal Justice Costs And Benefits Of Mental Health Interventions.....	9
OP41 Intercultural Medical Decision Support System Using Natural Language Processing (NLP).....	10
OP44 Robot-Assisted Surgery: Joint HTA To Inform Australian Policy And Funding.....	10
OP45 Biological Drugs And Rheumatoid Arthritis In Brazil: An Overview.....	11
OP47 Need For New Thrombectomy Centers? A Practical Decision Framework.....	11
OP48 Nursing Requirements In Long-Term Care: A Health Technology Assessment.....	11
OP49 MAIC-ing Use Of Trials? Study Of Matching-Adjusted Indirect Comparisons.....	12
OP50 IQWiG And GRADE – An Exemplary Comparison Of Methods.....	12
OP52 Use Of Intention To Treat And Magnitude Of Treatment Effects.....	12
OP53 Health Technology Assessment Acceptability Of Innovative Survival Metrics In Oncology.....	13
OP54 Monitoring Evidence On Overall Survival Benefits Of Anti-Cancer Drugs.....	13
OP56 Are Therapeutic Positioning Reports Driving Pharmaceutical Reimbursement Outcomes In Spain?.....	13
OP57 Threats And Opportunities To Digital Health In Primary Care.....	14
OP58 Developing An Evaluation Based Taxonomy For mHealth Apps.....	14
OP60 Challenges In Evaluating Smart Medical Devices.....	15
OP62 Let's Co-design A Tool To Assess Overweight And Obesity Health Apps.....	15

OP63 Clinical Videoconferencing - Critical-realist Review As Evidence?.....	15
OP64 Implementation Of Whole Exome Sequencing For Rare Diseases	16
OP65 Pharmacoeconomic Evaluation Of Orphan Drugs: Impact Of Extra Criteria?.....	16
OP68 Value-Engineered Translation: An Example for Bladder Cancer Diagnosis	17
OP69 Initiatives To Improve The Timeliness Of Cancer Diagnosis.....	17
OP71 Understanding Hospitals' Performance Variability: Conceptual Framework.....	17
OP72 HTA Beyond 2020 In China : HB-HTA Rising Up In Tertiary Hospitals	18
OP74 Stoma Cover Use By Fully Laryngectomized Patients	18
OP75 Facts And Values In Health Technology Assessment: The Case Of Non-Invasive Prenatal Testing.....	19
OP77 Nudging In Non-Invasive Prenatal Testing: Ethical Guidance	19
OP78 Picturing ELSI+: Mapping Ethical, Legal, Social And Value Issues	19
OP79 Improving Public Understanding Of Scottish Medicines Consortium Advice	20
OP80 Impact Of Patient Group Participation At Scottish Medicines Consortium Committee Meetings	20
OP81 Building Technical Capacity To Promote Patient Involvement In Health Technology Assessment	20
OP83 Iterative Formative Research Informing Primary Care Education Design	21
OP84 Collaborative Program To Improve Early Management Rheumatoid Arthritis.....	21
OP85 Persistence Leads To Ongoing Decreases In Primary Care Antibiotic Use	22
OP86 Exploring Public Utilization Data For Primary Care Education Programs.....	22
OP88 Digital Approaches For Randomized Controlled Trial Recruitment Or Retention: A Systematic Map.....	22
OP89 Conference Abstract Searching In National Institute For Health And Care Excellence Health Technology Appraisals.....	23
OP91 Developing A Celtic Connections Regional Health Technology Assessment Alliance	23
OP93 Collaboration Between Health Technology Assessment And Procurement: A Rapid Mixed-Methods Study	23
OP96 Assessing Impact Of UK Health Technology Assessment Programme Trials	24
OP97 Cost-effectiveness Model Appraisal Guidelines For Health Technology Assessments In Ireland.....	24
OP98 Limitations In Health-Economic Guidance For Medical Devices	25
OP103 Incorporating Health Technology Assessment In The Development Of A Clinical Care Pathway.....	25
OP105 Factors Affecting Horizon Scanning For Hospital-Based Health Technology Assessment.....	25
OP106 The Xpert™ Clostridium difficile Kit Incorporation: Conducting a Local Clinical Study as Part of Hospital Health Technology Assessment	26
OP109 The Need For Building Pharmacists' Health Technology Assessment Capacity; The Nigerian Scenario.....	26
OP112 Project Management for EUnetHTA Non-Pharmaceutical Technologies.....	27
OP115 Expanding Perspectives: The Role Of Environmental Scanning In Health Technology Assessment	27
OP122 Resource Use Measurement Issues: A Scoping Review.....	27
OP123 A Cost-Effectiveness Registry For Prioritization In Emerging Markets	28
OP124 Disinvestment – A Global Challenge Requiring Collaboration?	28
OP127 Sugar And Spice And All Things NICE - Managed Access Agreements.....	28
OP129 Healthcare Utilization After Bariatric Surgery.....	29
OP130 Evidence-Informed Policy For Biologic Medicines In Brazil.....	29
OP131 Rapid Review For Policy: Interchangeability Of Biological Medicines.....	30
OP132 What Future For Drugs After An Early Dialogue Procedure?	30
OP135 CAR T-cell Therapy HTA Informs Australian Policy	30
OP136 Provision Of A Chimeric Antigen Receptor T-Cell Program: A Rapid Review.....	31
OP137 Translating Results From Clinical Audit Studies To Local Context.....	31

OP138 Stakeholders' Involvement When Developing A mhealth Assessment Tool.....	31
OP140 Adult Patient Access To Electronic Health Records	32
OP142 Reviewing Methods For Early Assessment	32
OP143 Assessment Of mHealth Apps: Is Current Regulation Policy Adequate?	33
OP144 mHealth App Evaluation Framework For Reimbursement Decision-making.....	33
OP147 Educational Costs And Benefits Of Mental Health Interventions.....	33
OP151 Cost-Utility Of Gender-Neutral HPV Vaccination In Ireland.....	34
OP152 Pharmacoeconomic Assessment And Drug Expenditure Reduction In Ireland	34
OP157 Carbon Ion Radiotherapy: A Systematic Review.....	34
OP162 Stakeholder Involvement In EUnetHTA Relative Effectiveness Assessments.....	35
OP163 Health Technology Assessment Participation And Prioritization In Core Outcome Set Development	35
OP165 Health Technology Assessment And Public Health Priority Setting In China.....	36
OP168 The EUnetHTA Quality Management System: Development And Evaluation	36
OP169 Implementation Of A Quality Management System In The Spanish Network Of Health Technology Assessment.....	36
OP170 How Can Health Technology Assessment Participate In The Healthcare Quality Improvement?	37
Poster Presentations.....	37
PP02 Using Real World Data To Identify The Market For A New Technology.....	37
PP03 Development Of A Medical Device Maintenance Management System	37
PP05 The First Choice Of Health Institutions Of Elderly In Zhejiang And Qinghai, China	38
PP08 Evaluation Of The Brazilian Health Technology Assessment Network.....	38
PP09 Cost-Effectiveness Of Chronic Obstructive Pulmonary Disease Management.....	38
PP10 Quality Of Reporting Economic Evaluations In Rehabilitation Research	39
PP12 Cost-Utility Analysis Of Dolutegravir For HIV-1 Infection In Thailand.....	39
PP14 Budget Impact Of Sapropterin Dihydrochloride For Phenylketonuria.....	40
PP20 Challenges In The Health Technology Assessment Of New/Emergent Non-Pharmacological Technologies	40
PP21 High Risk Class Medical Devices Evaluation In Germany: Another Arzneimittelmarkt-Neuordnungsgesetz?	40
PP26 Shift From Regional To Federal Funding: Methodological Considerations.....	41
PP27 Additional Capabilities In Health Technology Assessment To Support Decision Making.....	41
PP28 Adoption Of Non-Pharmaceuticals In Galicia: Beyond Conventional Health Technology Assessment.....	41
PP30 Do Conditional Regulatory Pathways Affect Health Technology Assessment Recommendations?	42
PP31 Medical Device Regulation: What Is New?.....	42
PP32 Joint Early Dialogs Between Medical Device Regulation and Health Technology Assessment.....	43
PP34 Costs Of Healthcare-Associated Infections In Latin America	43
PP35 Valuing Intersectoral Costs And Benefits Of Interventions	43
PP36 Inflammatory Bowel Disease: The Disability Costs Among Italian Workers	44
PP38 Productivity Loss In Patients With Chronic Diseases: A Pooled Analysis	44
PP39 Budget Projections And Health Impact Of PD-1/PD-L1 Inhibitors.....	44
PP41 Cost-Effectiveness Modeling Of Chimeric Antigen Receptor T-Cell Therapies	45
PP43 Decision-Making Tool In Case Of Beta-Lactam Allergy: How To Help Clinicians?	45
PP44 Optimal Use Of Warfarin: Self-Monitoring From A Quebec Perspective	45
PP48 Risk Of Bias Of Systematic Reviews Connected To Journal Impact Factor?	46
PP50 How Do Target Population Sizes In Health Technology Assessments Impact Drug Price Changes?.....	46

PP52 Interim Decision-Making To Address Uncertainty At Early Assessment	46
PP54 A Cohort Case Study On Implantable Cardioverter Defibrillators	47
PP55 The Effectiveness Of Viabahn In Peripheral Artery Aneurysms.....	47
PP57 Outcomes On Transcatheter Aortic Valve Implantation.....	47
PP58 The Alliance Between Health Technology Assessment And Public Health In National Screening Policies	48
PP61 Advanced Therapy Medicinal Products Germany: Drugs Or Methods Review?	48
PP62 Cost-Effectiveness Of Cervical Cancer Screening In Estonia.....	49
PP64 Economic Evaluation For Esophageal Cancer Screening In China.....	49
PP65 Methods Applied For Systematic Reviews Of Economic Evaluations In Health Technology Assessment.....	49
PP66 Increasing Burden Of Out-Of-Pocket Healthcare Expense On Patients.....	50
PP68 Indicators From The Real World Data To Improve Opioid Use.....	50
PP69 Potential Gains In Health-Adjusted Life Expectancy From Reducing Four Non-Communicable Diseases Among Chinese Elderly.....	50
PP70 Identification Of Prostheses With Worse Than Expected Outcomes	51
PP72 Using INTEGRATE-HTA On The Example Of Rasterstereography For Scoliosis.....	51
PP78 Analysis Of Resource Utilization In Psoriasis Care In The Brazilian Health System.....	52
PP79 Impact Of Hidradenitis Suppurativa On Healthcare Resource Utilization	52
PP80 A Systematic Review Of The Gugging Swallowing Screen For Assessing Dysphagia	52
PP81 Real World Data: The Early Access To Medicines Scheme Catches The Worm	53
PP83 A Conceptual Decision-Making Framework For Pharmaceutical Innovations	53
PP84 Different Interpretation Of Evidence By A Health Technology Assessment Body And A Decision Maker.....	53
PP86 Reimbursement of Combination Oncology Products: Can Two (Companies) Tango?.....	54
PP87 Inpatient Drug Reimbursement: Approaches For A Democratic Process.....	54
PP88 Economic Impact Of New Diagnostic Tools In Severe Sepsis	55
PP89 Cost Effectiveness Of Hepatitis A Vaccination In India	55
PP93 Efficacy Of Pharmacological Treatments For Type 2 Diabetes In China.....	55
PP94 Clinical Effectiveness Of Regorafenib For Metastatic Colorectal Cancer.....	56
PP98 Educating Medical Students Toward Quality-Targeted Leadership	56
PP99 Hospital-Based Health Technology Assessment Units In Brazil: Present And Future.....	56
PP100 Unraveling Hospital-Based Health Technology Assessment In Brazil	57
PP103 A Comparative Study Of Catastrophic Health Expenditure In China	57
PP107 Harpoon™: A Novel Device For Transapical Mitral Valve Repair	57
PP108 Assessing CHA2DS2-VASc Score For Predicting Ischemic Stroke In The Non-Atrial Fibrillation Population.....	58
PP113 A Framework To Enhance Eurasian Economic Union Cooperation On Health Technology Assessment: Lessons From The European Network for Health Technology Assessment	58
PP121 How To Involve Patients In Decisions About Antibiotic Prophylaxis After Tick Bite	59
PP123 Management of Patients' Conflicts Of Interest And Of Commitment In Health Technology Assessment	59
PP124 Smart Capability Building For Effective Patient Involvement.....	59
PP125 PhotoVoice: Promoting Knowledge Exchange About Patients' Experiences.....	60
PP126 Analyses Of User Requirements In The Evaluation Of Medical Equipment.....	60
PP127 Asthma Patient Value Framework: Lessons From Patient Focus Groups.....	61
PP128 Quantifying The Relative Importance Of Chronic Obstructive Pulmonary Disease Symptoms To Patients.....	61
PP130 Oral Supplements For Protein-Energy Wasting In Chronic Kidney Disease	61

PP131 Omalizumab And Ciclosporin For Chronic Spontaneous Urticaria	62
PP132 Telemedicine Enhances Community Hospital Response Capacity	62
PP133 Ensuring Secure Health Data Exchange Across Europe. The SHIELD Project.....	62
PP135 Setting The Scope For Assessing e-Health Technologies In Hungary	63
PP136 How To Apply Health Technology Assessment To Large Scale e-Health Processes.....	63
PP137 Toric Intraocular Lenses and Spectacle Independence: A Systematic Review.....	64
PP139 Adapting Health Technology Assessment And Procurement To Tackle Antimicrobial Resistance.....	64
PP141 Functional Connectivity Magnetic Resonance Imaging To Detect Autism	64
PP142 Health Technology Assessment – A Major Bottleneck In Patient Access?.....	65
PP148 A Stakeholder-Informed Strategy For Effective Communication	65
PP150 Bevan Health Technology Exemplars: Early Dialogue To Systematize HTA.....	66
PP151 Establishing Health Technology Assessment Impact Evaluation With Stakeholder Input From Day One.....	66
PP155 Demand Side And Supply Side Of Healthcare Supply Chain	66
PP156 Reimbursement Of New Treatment Methods In Hospitals: Status In Germany.....	67
PP159 Is Community Paramedicine A Safe/Effective Alternative To Usual Care?.....	67
PP164 Improving Medical Diagnosis Through Advanced Data Analytics Tools.....	67
PP165 Content Instead Of Orders: Experiences Of Launching A Knowledge Base.....	68
PP166 A Mobile Clinical Decision Support System for Autism Spectrum Disorder.....	68
PP170 Quantifying the Life-Cycle Value of Second Generation Antipsychotics.....	69
PP171 Cost And Effectiveness Of Chronic Hepatitis C Treatment In Brazil.....	69
PP173 Is Early Modelling Too Late? Preventing Pitfalls And Optimizing Value.....	69
PP177 Health Preference Research In Europe: A Review Of Its Use.....	70
PP178 Health Technology Assessment Of Laboratory Medicine.....	70
PP179 Health Technology Assessment Of Pediatric Intensive Care Ventilators.....	70
PP182 Natalizumab Therapy For Relapsing-Remitting Multiple Sclerosis.....	71
PP185 Clinical Papers: Which Are Ongoing Studies To Assess mHealth In 2020?.....	71
PP186 Telemonitoring With Pacemakers For Patients With Heart Failure	72
PP187 Robotic Surgery, Any Updates?	72
PP189 Filling In The Blanks: Is RWE From MAAs Used In NICE Decision Making?.....	72
PP192 An Institutional Ethical Framework For HTA: Stakeholder Participation	73
PP193 How Does HTA Address Social Expectations Now? An International Survey.....	73
PP194 Intersectoral Costs And Benefits In The Societal Perspective.....	74
PP207 Evaluation On Effects Of Antimicrobial Stewardship In Tertiary Comprehensive Public Hospitals in Hainan, China.....	74
PP210 Identification Of Frailty to Healthy Ageing In European Population	74
PP238 Budget Impact Of Methionine-Free Amino Acid Formula For Homocystinuria.....	75

Vignette Presentations **75**

VP01 Methods Of Patient Involvement Now And Beyond 2020: A Case Study.....	75
VP02 Involving Patients In HTA Beyond 2020: A Thematic Review	75
VP04 The Influence Of Sponsorship On The Treatment Effects Of Trials	76
VP06 HTA And Health Industry: Key Aspect Of Their Relationships.....	76
VP07 Cost-Effectiveness Of HTA Fees.....	77
VP08 Can Health-Economic Evaluation Provide a Representation of ‘Value For Money’ For HTA?	77

VP11 Use Of Health Technology Assessment Adaptation In Latin America.....	77
VP13 Transferability Instrument Of Health Economic Evaluations For Chile.....	78
VP14 Cost Analysis For HD And Peritoneal Dialysis For ESRD In South Africa.....	78
VP15 Consumer Willingness To Pay For A Hypothetical Zika Vaccine In Brazil.....	78
VP16 A NICE Way To Manage Managed Access: Case Study In Muscular Dystrophy.....	79
VP18 Potential Of Real World Evidence For 'IDEAL' Procedures Research.....	79
VP19 Cost-Effectiveness Of Combination Inhaled Long-Acting Bronchodilators.....	80
VP21 Economic Burden Of Pertussis Treatment In Brazil, 2014.....	80
VP22 Applying The IDEAL Framework To NICE Interventional Procedure Guidance.....	80
VP23 Assessing The Effectiveness Of A Medical Device With Limited Evidence.....	81
VP25 HTA Enables Nurses To Discontinue Continuous ECG Monitoring.....	81
VP26 HTA In Nursing: Scoping Trends With An ICF Component Analysis.....	81
VP27 Countrywide Screening Of Cardiovascular Diseases Through Telemedicine.....	82
VP28 Building A Virtual Diagnosis Network Through A Telemedicine Platform.....	82
VP29 Designing A Mobile Clinical Decision Support System For Dementia.....	83
VP30 Evaluation Of CINAHL In Six Systematic Reviews On Maternal Care.....	83
VP31 Searching Non-English Literature For HTA Reports May Be Unnecessary.....	83
VP32 Incorporation Of The Only Drug For Primary Biliary Cholangitis Brazil.....	84
VP33 Pharmacoeconomic Submission Requirements: Africa Compared With England.....	84
VP34 Impact Of Adverse Events On Reimbursement Recommendations.....	84
VP35 Effectiveness and Safety of Cyanoacrylate Ablation for Varicose Veins.....	85
VP37 Patient Involvement In EUnetHTA Assessments (Non-Pharma Technologies).....	85
VP39 The Alphabet Lottery? How NICE Outcomes Vary By Appraisal Committee.....	86
VP40 Increasing Divergence Of IQWiG & G-BA Benefit Assessments Over Time?.....	86
VP41 NICE Interventional Procedures Advisory Committee Recommendations.....	86
VP46 German Claims Data In Rare Disease HTA: Diffuse Large B-cell Lymphoma.....	87
VP47 Secondary Prevention For CV Disease: Population And Outcomes Using RWD.....	87
VP49 Real-world Evidence For Economic Evaluation Of Medical Devices.....	87
VP53 Long-Acting Insulin Analogues In Brazil: Clinical And Economic Impact.....	88
VP54 Digital Tools For More Efficient Conduct Of RCTs: Trials Unit Survey.....	88
VP55 Trial Recruitment & Retention Using Digital Tools: A Qualitative Study.....	89
VP57 Using Capital Bids For Hospital-Based Health Technology Assessment.....	89
VP59 The MedicineWise App: Extended Applications Beyond Medicine Management.....	89
VP61 Rapid HTA Of The CarbonCool Full Body Suit For Exertional Heat Injuries.....	90
VP62 The EUnetHTA Companion Guide: A New Repository To Support European HTA.....	90
VP63 EUnetHTA Planned And Ongoing Projects Database: Usage And Challenges.....	90
VP65 HTA Beyond 2020: Need For "Professionalization"?.....	91
VP67 Caring For Children With Neurodevelopmental Disorders.....	91
VP71 Barriers To Access Biologic Products: A Rapid Review.....	92
VP72 Impact Of Comparator Choice On Oncology Drugs' Market Access.....	92
VP74 Orphan Black Box: Explanatory Principles.....	92
VP75 Improving Access To Ultra-Orphan Medicines In NHS Scotland.....	93

VP77 Extrapolating ICERs At Different Discount Rates	93
VP82 Impact of Evidence Synthesis Methods on Outcome of Economic Evaluation	93
VP83 Health Economics Distance Learning For Healthcare Workers In Brazil	94
VP89 A Preliminary Equity Checklist To Support The HTA Process	94
VP90 Which Matching Adjusted Indirect Comparison Method Is Best?	94
VP92 Portable Robotic Exoskeleton Stride Management Assist (SMA*)	95
VP95 Getting the Best Of 3 Ways-Merging EUnetHTA GRADE And Cochrane Guides	95
VP96 Activities To Optimize Quality And Efficiency Of Medicines In Scotland	96
VP98 Horizon Scanning For New Alternatives To The Treatment Of Leishmaniasis	96
VP99 Study On The Responsiveness Of Primary Medical Institution In ZJ & QH	96
VP100 Ultraradical Ovarian Cancer Surgery Comparative Clinical Effectiveness	97
VP101 Intrauterine Surgical Interventions: A Rapid Review	97